In contrast, in another model of BRCA1-deficient ovarian cancer, PARP inhibition induced a therapeutic effect through STING activation, showing synergic effects with PD-1 blockade on antitumor T-cell response and survival [185]. This evidence concerns the gene BRCA1 and ovarian cancer.